Sandra Horning, MD
The European Commission has approved atezolizumab (Tecentriq) for use in combination with carboplatin and nab-paclitaxel (Abraxane) for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer (NSCLC) who do not have EGFR
molecular aberrations, according to Roche (Genentech) the developer of the PD-L1 inhibitor.1
In the United States, the FDA is scheduled to make an approval decision on this atezolizumab regimen by December 2, 2019.
- European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Roche. Published September 6, 2019. Access September 6, 2019. https://bit.ly/2kmVbVV.
- Cappuzzo F, McCleod M, Hussein M, et al. IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol. 2018;29(supp 8, abstr LBA53). doi: 10.1093/annonc/mdy424.065.
... to read the full story